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Bridging integrator 1 protein loss in
Alzheimer’s disease promotes synaptic tau
accumulation and disrupts tau release
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Polymorphisms associated with BIN1 (bridging integrator 1) confer the second greatest risk for developing late-onset Alzheimer’s
disease. The biological consequences of this genetic variation are not fully understood; however, BIN1 is a binding partner for tau.
Tau is normally a highly soluble cytoplasmic protein, but in Alzheimer’s disease, tau is abnormally phosphorylated and accumu-
lates at synapses to exert synaptotoxicity. The purpose of this study was to determine whether alterations in BIN1 and tau in
Alzheimer’s disease promote the damaging redistribution of tau to synapses, as a mechanism by which BIN1 polymorphisms may
increase the risk of developing Alzheimer’s disease. We show that BIN1 is lost from the cytoplasmic fraction of Alzheimer’s disease
cortex, and this is accompanied by the progressive mislocalization of phosphorylated tau to synapses. We confirmed proline 216 in
tau as critical for tau interaction with the BIN1-SH3 domain and showed that the phosphorylation of tau disrupts this binding,
suggesting that tau phosphorylation in Alzheimer’s disease disrupts tau–BIN1 associations. Moreover, we show that BIN1 knock-
down in rat primary neurons to mimic BIN1 loss in Alzheimer’s disease brain causes the damaging accumulation of phosphory-
lated tau at synapses and alterations in dendritic spine morphology. We also observed reduced release of tau from neurons
upon BIN1 silencing, suggesting that BIN1 loss disrupts the function of extracellular tau. Together, these data indicate that
polymorphisms associated with BIN1 that reduce BIN1 protein levels in the brain likely act synergistically with increased tau
phosphorylation to increase the risk of Alzheimer’s disease by disrupting cytoplasmic tau–BIN1 interactions, promoting the
damaging mis-sorting of phosphorylated tau to synapses to alter synapse structure and reducing the release of physiological forms
of tau to disrupt tau function.
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Introduction
Tauopathies including Alzheimer’s disease are character-
ized by tau protein modifications that affect normal tau
interactions and localization and lead to the develop-
ment of neurofibrillary pathology (Guo et al., 2017).
The redistribution of highly phosphorylated and/or oli-
gomeric tau species to pre- and post-synapses causes the
disruption of synaptic vesicle mobility and neurotrans-
mitter release (Zhou et al., 2017; McInnes et al., 2018)
and excitotoxicity (Ittner et al., 2010; Li and Gotz,
2017), respectively. As a result, the accumulation of
phosphorylated tau at synapses is closely linked with
synapse loss and dementia in Alzheimer’s disease (Perez-
Nievas et al., 2013; Hanseeuw et al., 2019). Developing
a better understanding of the causes of tau protein re-
distribution to synapses may elucidate potential new
treatment strategies for Alzheimer’s disease and related
tauopathies.
Recent genome-wide association studies have identified
several gene variants that increase the risk of developing
Alzheimer’s disease. Of those identified to date, poly-
morphisms associated with bridging integrator 1 (BIN1)
confer the second largest genetic risk factor for develop-
ing sporadic Alzheimer’s disease, after the apolipopro-
tein E4 allele (APOE4) (Seshadri et al., 2010; Hu et al.,
2011; Wijsman et al., 2011; Lambert et al., 2013; Naj
et al., 2014; Vardarajan et al., 2015). Rare variants in
coding regions of BIN1 have been identified
(Vardarajan et al., 2015); however, the more common
BIN1 variants are upstream of the gene and do not af-
fect protein structure. However, these may affect the tis-
sue-specific splicing or expression of the cytoplasmic
membrane-binding BIN1 protein, which is known to
play important roles in endocytosis and subcellular traf-
ficking (Prokic et al., 2014). In support of this, the ex-
pression of the longer neuronal isoform of BIN1 is
decreased and the shorter glial isoforms are increased in
Alzheimer’s disease brain (Glennon et al., 2013; Holler
et al., 2014; De Rossi et al., 2016).
While most genetic variants that increase the risk of
Alzheimer’s disease affect b-amyloid generation and/or
clearance, BIN1 is relatively unusual in that its effects in
Alzheimer’s disease appear to be mediated by tau
(Chapuis et al., 2013; Wang et al., 2016). In Alzheimer’s
disease brain, BIN1 may colocalize with neurofibrillary
tangle-containing neurons (Holler et al., 2014) and is
associated with elevated tau phosphorylation (Wang
et al., 2016). Expression of BIN1 in a Drosophila model
of Alzheimer’s disease was shown to modulate the tox-
icity of tau (Chapuis et al., 2013) and the knockdown of
BIN1 promotes tau propagation between neurons
(Calafate et al., 2016). Others have shown that BIN1
over-expression in mice causes microstructural changes in
hippocampal circuits (Daudin et al., 2018) that are
among the first to show tau pathology in Alzheimer’s
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disease (Daudin et al., 2018), suggesting that BIN1 may
affect the development of Alzheimer’s disease by modulat-
ing tau effects at synapses, and possibly also synaptic
activity-dependent tau release (Pooler et al., 2013).
The effects of BIN1 on tau appear to be mediated by
direct association between the two proteins. Interactions
between BIN1 and tau have been demonstrated in cell
models, Drosophila and mice (Chapuis et al., 2013;
Sottejeau et al., 2015; Malki et al., 2017; Sartori et al.,
2019). BIN1 contains a src homology 3 (SH3) domain
through which it interacts with prolines within PXXP
motifs (Prokic et al., 2014). Tau contains seven PXXP
motifs in its proline-rich domain (Usardi et al., 2011),
and the SH3 domain of BIN1 interacts with the proline-
rich region of tau in a phosphorylation-dependent man-
ner (Chapuis et al., 2013; Sottejeau et al., 2015; Malki
et al., 2017; Sartori et al., 2019). However, the mecha-
nisms by which BIN1 affects tau to mediate pathological
changes in tau proteins are not fully understood. The
purpose of this study was to determine whether altera-
tions in BIN1 and tau in Alzheimer’s disease promote the
damaging redistribution of tau to synapses, as a mechan-
ism by which BIN1 polymorphisms may increase the risk
of developing Alzheimer’s disease.
Materials and methods
Human brain
Braak-staged post-mortem human temporal cortex was
obtained from the Medical Research Council London
Neurodegenerative Diseases Brain Bank at King’s College
London following ethical approval (Research Ethics
Committee reference: 08/MRE09/38þ 5). Neuropathological
assessment was performed according to standard criteria.
Samples were classified as control (no history of neurode-
generative or psychiatric disease and age-related path-
ology only), moderate Alzheimer’s disease (clinical
diagnosis of Alzheimer’s disease and Braak stage III–IV
pathology) and severe Alzheimer’s disease (clinical diag-
nosis of Alzheimer’s disease and Braak stage V–VI path-
ology). Characteristics of these samples are summarized
in Tables 1 and 2.
Modification of BIN1 expression in
primary neurons
All animal work was conducted in accordance with the
UK Animals (Scientific Procedures) Act 1986 and the
European Directive 2010/63/EU under UK Home Office
Personal and Project Licenses and with agreement from
the King’s College London (Denmark Hill) Animal
Welfare and Ethical Review Board.
Pregnant female Sprague-Dawley rats were purchased
from Charles River and were used within 1 day of deliv-
ery. Water and food were available (Picolab rodent diet
20; # 5053; Lab Diet, St Louis, MO, USA) ad libitum.
Animals were housed at 19–22C, humidity 55%, 12-
h:12-h light:dark cycle with lights on at 07:30. Primary
cortical neurons were dissected from embryonic day (E)
18 male and female rats and were cultured as previously
described (Pooler et al., 2012) on poly-D-lysine-coated
plates or glass coverslips. Rat neurons were used since
these provide a readily tractable cell model in which we
can mimic findings from post-mortem human brain and
they are a model in which ‘tau biology’ has been
Table 1 Summary of temporal cortex tissue used in
this study
Sex Age
(years)
Post-
mortem
delay (h)
Braak
stage
Diagnosis
F 74 64 II Control
F 90 44 II Control
F 73 27 I Control
F 77 21 0 Control
F 80 22 II Control
M 68 60 II Control
M 80 55 II–III Control
M 90 45 – Control
M 78 24 III Control
F 92 9 II Control
M 82 47 I Control
F 84 34 I–II Control
F 90 50 II Control
M 66 52 – Control
M 82 18 I/II Control
M 91 48 IV Moderate Alzheimer’s disease
M 88 79 III–IV Moderate Alzheimer’s disease
F 95 47 IV Moderate Alzheimer’s disease
M 84 86 IV Moderate Alzheimer’s disease
M 98 53 IV Moderate Alzheimer’s disease
F 86 55.5 IV Moderate Alzheimer’s disease
M 82 28 IV Moderate Alzheimer’s disease
M 86 52.5 IV Moderate Alzheimer’s disease
F 83 22 IV Moderate Alzheimer’s disease
M 93 13.5 IV Moderate Alzheimer’s disease
F 83 41.5 IV Moderate Alzheimer’s disease
F 97 67.5 III–IV Moderate Alzheimer’s disease
F 96 39 IV Moderate Alzheimer’s disease
F 92 19.5 III Moderate Alzheimer’s disease
F 92 29.5 IV Moderate Alzheimer’s disease
F 73 30 VI Severe Alzheimer’s disease
F 84 27 VI Severe Alzheimer’s disease
F 79 31 VI Severe Alzheimer’s disease
M 86 38 VI Severe Alzheimer’s disease
F 85 79 VI Severe Alzheimer’s disease
M 67 39.5 VI Severe Alzheimer’s disease
F 69 73 VI Severe Alzheimer’s disease
F 89 38.5 VI Severe Alzheimer’s disease
F 93 49 VI Severe Alzheimer’s disease
M 84 67 VI Severe Alzheimer’s disease
F 81 20 VI Severe Alzheimer’s disease
M 83 22 VI Severe Alzheimer’s disease
F 81 17.5 VI Severe Alzheimer’s disease
F 86 25 VI Severe Alzheimer’s disease
M 66 41 VI Severe Alzheimer’s disease
Table shows details of sex, age, post-mortem delay, Braak stage and Alzheimer’s dis-
ease diagnosis for cases from which frozen temporal cortex sections was obtained.
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extensively studied. Lentivirus short hairpin RNA
(shRNA) targeting BIN1 from the RNA interference con-
sortium (TRCN0000088188) and a scrambled control se-
quence in the pLKO.1 vector were purchased from
Dharmacon Horizon (CO, USA). PAX2 and pMG.2 lenti-
viral packaging vectors were kind gifts from Dr Maria
Jimenez-Sanchez (King’s College London). Human embry-
onic kidney (HEK293) cells cultured in Dulbecco’s
Modified Eagle’s Medium plus GlutaMAX (Thermo
Fisher Scientific, MA, USA) supplemented with 10% (v/v)
foetal bovine serum (Thermo Fisher Scientific) were trans-
fected with PAX2, pMG.2 and shRNA lentivirus using
Lipofectamine 2000 (Invitrogen, CA, USA). After 24 h,
lentiviral particles were collected from culture medium,
isolated and concentrated according to the manufacturer’s
instructions. For lentiviral knockdown, neurons were cul-
tured for 5 days in vitro (DIV) and then treated with ei-
ther BIN1 targeting shRNA, scrambled or control shRNA
lentiviral particles for 24 hours, after which time the virus
was removed and neurons further cultured until 21–23
DIV prior to use. Alternatively, BIN1 was knocked down
in primary neurons using Accell BIN1 small interfering
RNA smart pool (E-095528) purchased from Dharmacon
Horizon Discovery (UK). For these experiments, 19 DIV
rat primary cortical neurons were transfected with 50 nM
BIN1 or non-targeting control small interfering RNA
(Dharmacon Horizon Discovery) using Lipofectamine
2000 for 96 h at 37C, after which time neurons were
imaged or harvested.
Tau enzyme-linked immunosorbent
assay and cell viability assays
Tau enzyme-linked immunosorbent assays were per-
formed on Hank’s balanced salt solution with Ca2þ and
Mg2þ medium that had been incubated for 4 h with 22–
23 DIV primary neurons as we described previously
(Croft et al., 2017). The amount of lactate dehydrogenase
in the media of cultured neurons was determined as a
measure of neuron heath, using an LDH Cytotoxicity Kit
from Thermo Fischer Scientific according to the manufac-
turer’s instructions.
Immunofluorescence
Immunofluorescence was performed as described previ-
ously (Schurmann et al., 2019), using 2% (v/v) foetal bo-
vine serum (Life Technologies) in place of normal goat
serum. Cells were incubated with primary antibodies
against BIN1 (ab54764; Abcam), post-synaptic density 95
(PSD95, D74D3; Cell Signaling), synaptophysin (sc7568;
Santa Cruz, TX, USA), glial fibrillary acidic protein
(Agilent, ZO334) and microtubule-associated protein 2
(GTX82661; GeneTex) and the appropriate species of
AlexaFluor-conjugated secondary antibodies (Life
Technologies). Coverslips were mounted onto glass slides
using the ProLong Diamond mounting media (Life
Technologies). The labelled proteins were imaged under
an Eclipse Ti2 inverted Nikon 3D structured illumination
microscope, and images were reconstructed using Nikon
Imaging Systems Elements software, or a Nikon Eclipse
Ti2 inverted microscope with Vt-iSIM scan head and
deconvolved using Nikon Imaging Systems Elements
software.
Analysis of synapses
Primary neurons were fractionated to generate cytosol-
and synapse-enriched fractions using a protocol modified
from Frandemiche et al. (2014). Total, cytosolic and syn-
aptoneurosome fractions were isolated from post-mortem
temporal cortex as we described previously (Perez-Nievas
et al., 2013). Equal protein amounts of total, synaptic
and cytoplasmic fractions were immunoblotted.
For the analysis of dendritic spine structure, neurons at
22 DIV were transfected with an enhanced green fluores-
cent protein-N2 plasmid (Clontech, Kyoto, Japan) using
Lipofectamine 2000, fixed 24 hours post-transfection,
and the GFP-expressing cells were imaged using a Nikon
Eclipse Ti2 inverted microscope with Vt-iSIM scan head.
The 3  3 large image stacks were acquired covering the
entire volume of the neuron, with 0.2 lm between each
image in the Z plane. NeurolucidaTM software (MBF
Bioscience, VT, USA) was used to trace neurons and de-
tect, classify and quantify dendritic spines and perform
the Scholl analysis. Neuronal complexity was determined
by (sum of the terminal orders þ number of terminals) 
(total dendritic length/number of primary dendrites),
where terminals are the number of branch endings and
terminal orders are the number of branches between the
terminal and the cell body.
Glutathione-S-transferase binding
assays
BIN1-SH3 cDNA generously provided by Isabelle
Landrieu (University of Lille Nord de France) was cloned
into pGEX5X1 vectors using sequence- and ligation-inde-
pendent cloning (Hill and Eaton-Rye, 2014). The BIN1-
SH3 domain was amplified from the original vector using
Table 2 Summary of temporal cortex cases and con-
trols used in this study
Disease
stage
Female
(%)
Age (years),
mean6 SEM
Post-mortem
delay (h), mean6
SEM
Control 53.3 80.46 2.07 38.16 4.40
Moderate 57.1 89.66 1.42 45.36 5.50
Severe 64.2 80.96 2.10 39.86 5.00
Table shows the percentage of control, moderate Alzheimer’s disease and severe
Alzheimer’s disease cases that were female, the mean age at death (6 SEM) and the
mean post-mortem delay (6 SEM).
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primers 50-TCG AGC GGC CGC ATC GTG ACA TGG
GTC GTC TGG ATC TG-30 and 50-AAA CGC GCG
AGG CAG ATC GTC AGT TAC GGC ACA CGC TCA
GTA AAA TTC-30, and pGEX5X1 was linearized using
primers 50-CTG ACG ATC TGC CTC GCG-30 and 50-
GTC ACG ATG CGG CCG CTC-30. Sequence- and liga-
tion-independent cloning products were used to transform
BL21 E. coli (New England Biolabs, MA, USA) by heat
shock. DNA was purified using the QIAgen Spin
Miniprep Kit (QIAgen, Hilden, Germany), and the clon-
ing was confirmed by sequencing (Source Bioscience,
Nottingham, UK), using stock primers to the glutathione-
S-transferase (GST) plasmid. BL21 E. coli containing ei-
ther BIN1-SH3-pGEX5X1 or empty vector pGEX5X1
was used to produce GST fusion proteins. Wild-type
human 2N4R tau and PXXP mutant tau plasmids have
been described previously (Lau et al., 2016). These were
expressed in HEK293 cells for 24 h after which time cells
were lysed and the lysates used for GST pull-downs,
which were performed as we described previously (Lau
et al., 2016).
Sodium Dodecyl Sulfate–
Polyacrylamide Gel Electroresis and
western blotting
Protein concentrations of samples were determined using
a BCA protein assay kit (Thermo Fisher Scientific) and
Ponceau Red staining of membranes. Equal protein
amounts were electophoresed on 10% tris-glycine SDS-
polyacrylamide gels, Nu-Page 4–12% or 10% bis–tris
gels (Invitrogen), transferred to 0.45-lm nitrocellulose
membrane (Millipore, MA, USA) and immunoblotted
using standard methods. Primary antibodies were BIN1
(99D; Millipore), GST (GE Healthcare, IL, USA), total
tau (total human tau; Agilent), Tau-1 (Millipore), PHF1
(Peter Davies, Donald and Barbara Zucker School of
Medicine at Hofstra, Northwell), N-methyl-D-aspartate
subunit 2B (06-600; Millipore), b-actin (ac15; Abcam),
synaptophysin (sc17750; Santa Cruz), PSD95 (MAB
1596; Millipore) and Fyn (HPA023887; Sigma). The
bound horseradish peroxidase-conjugated secondary anti-
bodies (GE Healthcare) were detected using enhanced
chemiluminesence solutions (Thermo Fisher Scientific) and
visualized using a ChemiDoc imager (Bio-Rad, CA, USA).
Densitometric analysis was performed using FIJI.
Data analysis and statistics
Statistical tests were performed using GraphPad Prism
7.0 (CA, USA) or RStudio. Normality tests were per-
formed on all data, and the appropriate statistical tests
were then used to determine differences between experi-
mental groups. Tests used and sample size (n) numbers
are provided for each experiment in the figure legends.
Data availability
The data supporting this study are available in the manu-
script and Supplementary Material, and raw data will be
made available on reasonable request following publica-
tion. Summary statistics including exact P-values, F-values
and degrees of freedom are included in the
Supplementary Material.
Results
BIN1 loss in cytoplasmic fractions
correlates with increased synaptic
tau in Alzheimer’s disease brain
In Alzheimer’s disease, highly phosphorylated tau is mis-
localized to synaptic compartments (Perez-Nievas et al.,
2013) where tau disrupts synapse function and mediates
synaptotoxicity (Ittner et al., 2010; Li and Gotz, 2017;
Zhou et al., 2017; McInnes et al., 2018). The longest
neuronal isoform of BIN1 protein is reduced in end-stage
Alzheimer’s disease brain (Glennon et al., 2013; De Rossi
et al., 2017). To determine whether BIN1 is lost at the
earlier stages of Alzheimer’s disease, and whether its loss
is associated with changes in the distribution of tau, we
isolated synaptoneurosomes (Perez-Nievas et al., 2013)
from control (Braak stage 0–III), moderate (Braak stage
III–IV) and severe (Braak stage V–VI) post-mortem
Alzheimer’s disease temporal cortex and examined total,
cytosolic and synaptic fractions on western blots (Fig. 1).
The integrity of synaptic proteins in these samples was
first confirmed, as described previously (Bayes et al.,
2014), by western blotting a subset of samples with an
antibody against N-methyl-D-aspartate subunit 2B
(Supplementary Fig. 1B and C). Relatively little degener-
ation of synaptic proteins indicating that acceptable levels
of synaptic integrity is maintained in these tissues (Bayes
et al., 2014), and showed no differences in synaptic integ-
rity between groups.
In total brain homogenates, we confirmed a trend to-
wards reduction in BIN1 in severe relative to moderate
stage Alzheimer’s disease and control tissues (Fig. 1A and
B) and significant increases in total and phosphorylated
tau amounts with increasing disease severity (Fig. 1A, C
and D), as previously reported (Kurbatskaya et al.,
2016). Protein amounts were normalized to neuron-spe-
cific enolase in the same sample prior to quantification to
control for any effects of neuronal loss and/or gliosis
(Kurbatskaya et al., 2016). Tau phosphorylation was
detected using an antibody against tau phosphorylated at
S396/404 (PHF1). The cytoplasmic and synaptoneuro-
some fractions isolated from the same brain samples were
characterized to confirm their relative purity
(Supplementary Fig. 1A). Blotting of these samples
showed a significant accumulation of tau and phosphory-
lated tau in the synaptic compartment in severe
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Figure 1 BIN1 and tau are lost from the cytoplasm, and this is associated with the accumulation of phosphorylated tau at
synapses in Alzheimer’s disease temporal cortex. (A) Total homogenates from temporal cortex of control (Braak stage 0–III), moderate
(Braak stage III–IV) and severe (Braak stage V–VI) Alzheimer’s disease brain were western blotted using antibodies against BIN1, total tau,
phosphorylated tau (PHF1, pSer396/404) and neuron-specific enolase (NSE) as a loading control. Bar charts show the quantification of (B) BIN1,
6 | BRAIN COMMUNICATIONS 2020: Page 6 of 16 E. B. Glennon et al.
(continued)
D
ow
nloaded from
 https://academ
ic.oup.com
/braincom
m
s/article/2/1/fcaa011/5736128 by guest on 22 Septem
ber 2020
Alzheimer’s disease brain, relative to moderate staged
samples and controls (Fig. 1E, G and H). Tau phos-
phorylated at S396/S404 was found to accumulate at syn-
apses in both moderate and severe stage Alzheimer’s
disease relative to controls (Fig. 1E and H). The accumu-
lation of synaptic tau paralleled the loss of cytoplasmic
tau (Fig. 1I, K and L), suggesting that these results reflect
tau mis-sorting from the cytoplasm to synapses. There
were no differences in BIN1 levels in synaptoneurosomes
between groups (Fig. 1E and F). However, we found
marked and significant losses of cytoplasmic BIN1 in
both moderate and severe Alzheimer’s disease tissues
(Fig. 1I and J) that correlated positively with reductions
in cytoplasmic tau (Fig. 2A) and inversely with increased
synaptic tau (Fig. 2C and D). We also found negative
correlations between levels of phosphorylated (pSer396/
404, PHF1) tau and BIN1 in the cytoplasmic fraction
(Fig. 2B). There were also no significant correlations be-
tween total tau or phosphorylated tau and BIN1 amounts
in either the total or synaptoneurosome fractions
(Supplementary Fig. 1G–J). Taken together, these data
suggest that loss of cytoplasmic BIN1 may facilitate the
mis-sorting of phosphorylated tau to the synapse.
BIN1 knockdown causes synaptic
accumulation of phosphorylated tau
in neurons
To model BIN1 loss and tau mislocalization to synapses
in vitro, we silenced BIN1 in rat primary cortical neurons
using lentivirus. We confirmed the efficiency of BIN1
knockdown by western blotting and proximity ligation
assay (Supplementary Fig. 2). In control neurons, BIN1
and tau are found in fractions enriched in cytoplasmic
and synaptic proteins (Fig. 3A). Nikon 3D structured illu-
mination microscope imaging of neuronal processes
showed that BIN1 decorates microtubule-associated pro-
tein 2-positive and microtubule-associated protein 2-nega-
tive fibres (Fig. 3B) and localizes in close proximity to
pre-synaptic (synaptophysin) and post-synaptic (PSD95)
markers, with a portion of BIN1 co-localizing with
PSD95 (Fig. 3C). Cultures were also immunolabelled
with an antibody against glial fibrillary acidic protein,
which suggests that a small proportion of BIN1 is astro-
cytic (Supplementary Fig. 2I and J), in agreement with re-
cent reports (Taga et al., 2019).
We found that knockdown of BIN1 did not alter the
total amount of tau or its phosphorylation in total cell
lysates (Supplementary Fig. 2A–D). However, following
BIN1 knockdown, there was a significant increase in the
amounts of phosphorylated, but not total or dephos-
phorylated, tau in synapse-enriched fractions relative to
controls (Fig. 3D–G). These data show that reducing
BIN1 in neurons causes the accumulation of
Figure 1 Continued
(C) tau and (D) tau phosphorylated at Ser396/404 (PHF1). Data shown are mean6 SEM expressed as fold average control. n¼ 13 per group
(BIN1), n¼ 14 per group (tau) or n¼ 12 per group (PHF1). Following D’Agostino and Pearson normality testing, data were analysed using a one-
way ANOVA with Holm–Sidak’s multiple comparisons test. (E) Synaptoneurosomes isolated from the same temporal cortex samples were
immunoblotted with the same antibodies. Bar charts show the quantification of (F) BIN1, (G) tau and (H) PHF1 in synaptoneurosome fractions
following normalization. Data are mean6 SEM expressed as fold average control. n¼ 15 per group (BIN1 and tau) or n¼ 12 per group (PHF1).
Following D’Agostino and Pearson normality testing, data were analysed using non-parametric Kruskal–Wallis test with Dunn’s multiple
comparison test. (I) The cytoplasmic fraction was blotted as above with antibodies against BIN1, tau, PHF1 and NSE. Bar charts show the
quantification of (J) BIN1, (K) tau and (L) tau phosphorylated at Ser396/404 (PHF1) in the cytoplasmic fraction following normalization to NSE in
the same sample. Data are mean 6 SEM expressed as fold mean control. n¼ 11 per group (BIN1) or n¼ 12 per group (tau and PHF1). Following
D’Agostino and Pearson normality testing, BIN1 data were analysed using non-parametric Kruskal–Wallis test with Dunn’s multiple comparison
test and tau data using a one-way ANOVA with Holm–Sidak’s multiple comparisons test. *P< 0.05, **P< 0.01, ***P< 0.001 and ****P< 0.0001.
Full uncut western blots are found in the Supplementary Material.
Figure 2 Loss of BIN1 correlates with the loss of
cytoplasmic tau and increased synaptic tau in Alzheimer’s
disease temporal cortex. Correlation analysis of (A) BIN1 and
tau amounts and (B) BIN1 and phosphorylated (pSer396/404,
PHF1) tau amounts in the cytoplasmic fractions showing a strong
positive correlation between BIN1 and total tau, a negative
correlation between BIN1 and phosphorylated tau (n¼ 38) and
strong negative correlations between (C) cytoplasmic BIN1 and
synaptic tau (n¼ 38) and (D) cytoplasmic BIN1 and synaptic tau
phosphorylated at Ser396/404 (PHF1) (n¼ 36). Colours represent
control (green), moderate (blue) and severe (purple) Alzheimer’s
disease samples.
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Figure 3 BIN1 knockdown in neurons increases the abundance of phosphorylated tau at synapses. (A) Proteins from 22 DIV
primary cortical neurons were biochemically fractionated using a synaptosome fractionation protocol into total, synaptic protein- (syn) and
cytoplasmic (cyto) protein-enriched fractions, which were western blotted with antibodies against PSD95, tubulin, tau and BIN1. Blots show the
presence of BIN1 and tau in all fractions and an enrichment of PSD95 in the synaptic relative to the cytosolic fraction. (B) N-SIM super-
resolution images of primary cortical neurons immunolabelled with antibodies against BIN1 (ab54764, pink) and the dendritic marker MAP2
(blue) showing that BIN1 is present within dendrites and axons in cultured neurons. (C) N-SIM super-resolution images show close associations
and some colocalization of BIN1 (ab54764, blue) with the pre-synaptic marker synaptophysin (green) and the post-synaptic marker PSD95 (pink).
(D) Lysates from primary cortical neurons transduced with scrambled control shRNA (Scr) lentivirus or BIN1 shRNA (BIN1) lentivirus at 5 DIV
and biochemically fractionated at 22 DIV as above were immunoblotted with antibodies against BIN1, total tau, tau phosphorylated at Ser396/
404 (PHF1), tau dephosphorylated at Ser199/202/Thr205 (Tau-1), Fyn kinase and PSD95. Bar charts show the quantification of synaptic (E) total
tau, (F) tau phosphorylated at Ser396/404 (PHF1), (G) dephosphorylated tau (Tau-1) and (H) Fyn protein amounts. Data were normalized to the
synaptic marker PSD95 in the same sample and are expressed as percentage mean control (scrambled shRNA). Data are mean 6 SEM and were
analysed using Mann–Whitney test. n¼ 4-5, **P< 0.01. Full uncut western blots are found in the Supplementary Material. MAP2 ¼ microtubule-
associated protein 2; N-SIM ¼ Nikon 3D structured illumination microscope.
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phosphorylated tau at synapses and suggest that the
increased synaptic phospho-tau that we observe in post-
mortem Alzheimer’s disease brain may result from tau
mislocalization from the cytoplasm upon the loss of cyto-
plasmic BIN1.
When bound to tau, the non-receptor tyrosine kinase,
Fyn, is trafficked to the post-synapses where it is believed
to mediate b-amyloid toxicity in Alzheimer’s disease
(Ittner et al., 2010). We previously showed that the Fyn-
SH3 domain also binds preferentially to proline 216 in
tau (Usardi et al., 2011; Pooler et al., 2012). We there-
fore examined the localization of Fyn in synaptic frac-
tions following BIN1 knockdown. Our data suggest that
there is no competition between BIN1 and Fyn for bind-
ing to tau since we found no alterations in synaptic Fyn
amounts in neurons treated with BIN1 shRNA (Fig. 3H).
The interaction of BIN1 with tau is reported to be
regulated by tau phosphorylation and via direct associ-
ation of the BIN1-SH3 domain and the proline-rich re-
gion of tau (Sottejeau et al., 2015; Lasorsa et al., 2018).
To confirm this, we generated GST-BIN1-SH3 constructs
(Supplementary Fig. 3A) and we used these and GST-
only constructs in binding assays using lysates from
HEK293 cells transfected with wild-type human 2N4R
tau, mutant tau constructs or empty vector. The mutant
tau constructs are human 2N4R tau in which a single
proline in each PXXP motif is mutated to alanine
(Supplementary Fig. 3B), as we reported previously (Lau
et al., 2016). Immunoblotting of BIN1-SH3-GST pull-
downs with an antibody against tau confirmed that the
BIN1-SH3 domain binds human 2N4R tau
(Supplementary Fig. 3A and Fig. 4A and B). The analysis
of BIN1-SH3 binding to mutant relative to wild-type
human tau showed that P216 is important for the tau–
BIN1 interaction. The amount of P216A tau bound to
BIN1-SH3 was significantly decreased relative to wild-
type tau. There were no significant differences relative to
wild type in tau binding to BIN1-SH3 when any other
proline residue was mutated to alanine (Fig. 4A and B).
We next confirmed that increasing tau phosphorylation,
to mimic tau modifications in Alzheimer’s disease, affects
the interaction of tau with BIN1 in cultured primary rat
neurons. Cells were treated for 4 h with 50 nM okadaic
acid, a protein phosphatase inhibitor that prevents the re-
moval of phosphate from residues throughout the tau
molecule to allow efficient tau phosphorylation (Van
Dolah and Ramsdell, 1992; Pooler et al., 2012)
(Fig. 4C). GST pull-downs with lysates from these cells
confirmed that phosphorylated tau shows only trace
amounts of binding to BIN1-SH3-GST when compared
with lysates from vehicle-treated cells (Fig. 4D). When
tau was dephosphorylated upon application of 25mM of
the glycogen synthase kinase-3 inhibitor lithium chloride
(Stambolic et al., 1996; Pooler et al., 2012) (Fig. 4E and
F), or 20 lM of the casein kinase-1 inhibitor IC261
(Pooler et al., 2012) (Supplementary Fig. 4), the amount
of tau pulled down by BIN1-SH3 was similar to controls.
Glycogen synthase kinase-3 and casein kinase-1 inhibitors
were used to modulate tau phosphorylation since these
kinases phosphorylate tau throughout the protein (Guo
et al., 2017), and phosphorylation of tau sites distal and
proximal to P216 mediates tau interactions with BIN1-
SH3 (Sottejeau et al., 2015; Lasorsa et al., 2018). These
data confirm and extend previous findings to show that
BIN1-SH3 interacts with P216 in tau, predominantly
when tau is dephosphorylated. Taken together, our data
suggest that tau phosphorylation in Alzheimer’s disease
may disrupt cytoplasmic BIN1–tau interactions and allow
unbound tau to mislocalize to synapses.
Loss of BIN1 alters spine
morphology and reduces tau
release from neurons
Synaptic tau is closely linked with the release and propa-
gation of modified tau proteins in Alzheimer’s disease
and related tauopathies (Guo et al., 2017; Yamada,
2017). However, the release of soluble tau species in
physiological conditions allows important signalling roles
of extracellular tau (Gomez-Ramos et al., 2008; Pooler
et al., 2013) and this tau function may be lost in
Alzheimer’s disease (Croft et al., 2017).
Tau release is predominantly mediated by synaptic ac-
tivity, and modulating BIN1 expression affects dendritic
spine morphology and a-amino-3-hydroxy-5-methyl-4-iso-
xazolepropionic acid (AMPA) receptor-mediated synaptic
transmission via changes in AMPA receptor surface ex-
pression and trafficking (Daudin et al., 2018; Schurmann
et al., 2019). Since we and others have previously shown
that neuronal depolarization and stimulation of AMPA
receptors mediate endogenous tau release (Pooler et al.,
2013; Croft et al., 2017), we examined the effects of
BIN1 knockdown by shRNA on synapse morphology
and tau release. Examination of neurons by iSIM showed
that BIN1 knockdown affects synaptic morphology in 23
DIV primary neurons exogenously expressing enhanced
green fluorescent protein. BIN1 knockdown did not cause
any alterations in dendritic spine length, volume or dens-
ity (Fig. 5A–D) but resulted in significant increases in the
diameter of spine heads and necks (Fig. 5E and F) and a
reduced head:neck diameter ratio (Fig. 5G). When spine
morphologies were examined, BIN1 knockdown had no
effect on the proportion of immature stubby or thin
spines (Fig. 5H and I) but significantly reduced the pro-
portion of filopodia (Fig. 5K) and increased the propor-
tion of mature mushroom spines (Fig. 5J), which are
relatively stable and have a high density of AMPA recep-
tors (Hanley, 2008; Lee et al., 2012; Woolfrey and
Srivastava, 2016). The structure and density of dendritic
spines varies according to the branch order of the neu-
rite, and Scholl analysis (Supplementary Fig. 5) showed
that BIN1 knockdown increases the branching of den-
drites and increases neuronal complexity, which may
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Figure 4 BIN1 and tau interact via BIN1-SH3 and P216 in tau in a phosphorylation-dependent manner. (A) HEK293 cells were
transfected with WT 2N4R tau or PXXP mutant tau constructs in which a single proline residue at sites 176, 182, 200, 206, 213, 216, 219 or 223
was mutated to alanine to disrupt the PXXP sequence. Proteins in lysates from HEK293 cells (input) were pulled down with BIN1-SH3-GST
beads and western blotted with antibodies against total tau or GST. (B) The amount of WTor PXXP mutant tau pulled down by BIN1-SH3-GST
was quantified, and the bar chart shows this data relative to WT 2N4R tau (control). When P216 was mutated to alanine, tau binding to BIN1-
SH3 was significantly reduced (**P< 0.001). Following D’Agostino and Pearson normality testing, data were analysed using non-parametric
Kruskal–Wallis test and Dunn’s multiple comparisons test. Data shown are mean 6 SEM, n¼ 9. (C) Primary cortical neurons were treated with
either vehicle () or 50 nM OA (þ) for 4 h. Proteins were pulled down from primary neuron lysates with BIN1-SH3-GST. Western blots of
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contribute to the difference in spine structure that we ob-
serve since spines on all branches of neurites were
quantified.
To determine whether BIN1 knockdown affects tau re-
lease, tau content in culture medium from 21 DIV neu-
rons treated with BIN1 and control shRNA was
measured by enzyme-linked immunosorbent assay and
normalized to the total amount of tau in neurons from
the same culture well, as we reported previously (Croft
et al., 2017). BIN1 knockdown caused a significant re-
duction in basal tau release without affecting the amount
of intracellular tau (Fig. 6A–C). BIN1 knockdown fol-
lowed by the depolarization of neurons with potassium
chloride to stimulate tau release (Pooler et al., 2013;
Croft et al., 2017) also significantly reduced tau release
relative to controls (Fig. 6D–F). The observed changes in
tau release were not due to cell toxicity since there were
no alterations in lactate dehydrogenase content in me-
dium between conditions (Fig. 6G). Thus, BIN1 knock-
down results in alterations in synapse morphology and
reduces basal and stimulated tau release. Our findings,
therefore, suggest that since BIN1 knockdown affects tau
release, loss of BIN1 in Alzheimer’s disease will disrupt
the functions of extracellular tau in addition to allowing
phosphorylated tau to mislocalize to synapses and exert
toxicity. Our data provide novel insights into the mecha-
nisms by which BIN1 polymorphisms may increase the
risk of Alzheimer’s disease.
Discussion
BIN1 is closely linked with tau abnormalities that under-
lie the progression of sporadic Alzheimer’s disease
(Chapuis et al., 2013; Calafate et al., 2016; Dourlen
et al., 2019; Sartori et al., 2019). Our results suggest that
BIN1 and tau interact predominantly when tau is dephos-
phorylated in the cytoplasm and that altered tau phos-
phorylation, together with BIN1 loss in Alzheimer’s
disease, allows tau to be mislocalized to synapses where
it is detrimental to synapse health. In support of this, we
found that P216 of tau interacts with the BIN1-SH3 and
that interactions between these two proteins are disrupted
when tau phosphorylation is increased in primary neu-
rons. Our results also indicated that there may be some
loss of tau interactions with BIN1-SH3 when tau proline
219 was mutated to alanine. Notably, even when an ap-
parent (but not statistically validated) outlier was
removed from this analysis, binding of BIN1-SH3 with
P219A mutant tau was not significantly reduced.
However, others have reported that proline residues 216
and 219 of tau are in direct contact with BIN1 (Lasorsa
et al., 2018). Our findings also showed that treatment
with OA to increase tau phosphorylation effectively abol-
ished tau interactions with BIN1. This is in keeping with
observations of tau interactions with other SH3 domain-
containing proteins such as Fyn (Reynolds et al., 2008;
Usardi et al., 2011; Pooler et al., 2012). Nevertheless, it
is somewhat surprising that the binding of tau with BIN1
is not increased from baseline when tau is dephosphory-
lated since a degree of tau phosphorylation is expected in
basal cell culture conditions. Future experiments using
tau phosphomimics in which tau residues are mutated to
mimic permanent phosphorylation or dephosphorylation,
or conducting dose response experiments with tau phos-
phorylation modulators, will be useful to fully examine
the effects of tau phosphorylation on its interactions with
BIN1.
Loss of BIN1 from Alzheimer’s disease cytoplasm at
moderate and severe stages of disease was accompanied
by the accumulation of phosphorylated tau in synaptic
compartments. The average age of patients classified as
‘moderate’ Alzheimer’s disease on the basis of Braak
stage was found to be significantly higher than those
with severe Alzheimer’s disease, and this may indicate
that our ‘severe’ Alzheimer’s disease group consisted of
cases with increased resilience to the accumulation of
Alzheimer’s disease pathology. Our analysis of the rela-
tionship between phosphorylated tau and BIN1 subcellu-
lar distributions was conducted independently of Braak
stage and, therefore, we do not consider this to confound
our findings. However, it could be of interest to examine
the relationship between tau and BIN1 further in well-
matched resilient and susceptible populations in future
studies.
Figure 4 Continued
neuronal lysates (input) with antibodies against total tau, tau phosphorylated at Ser394/404 (PHF1) and tau dephosphorylated at Ser199/202/Thr
205 (Tau-1) show increased tau phosphorylation following OA treatment. (D) Quantification shows that the amount of tau pulled down by
BIN1-SH3-GST is reduced following OA treatment of primary neurons. Data are shown as percentage relative to the mean of controls (vehicle).
Following Shapiro–Wilk normality testing, the data were analysed using an unpaired T-test. Data shown are mean 6 SEM, n¼ 4. ****P< 0.0001.
(E) Lysates from primary cortical neurons show reduced tau phosphorylation following treatment with 25 mM LiCl (þ) for 4 h relative to
vehicle-treated neurons (). BIN1-SH3-GST pull-downs show that there was no difference in the amount of tau pulled down by BIN1-SH3-GST
following LiCl treatment relative to vehicle-treated conditions. (F) Quantification shows no difference in the amount of tau from vehicle- or
LiCl-treated neurons pulled down by BIN1-SH3-GST. Following Shapiro–Wilk normality testing, data were analysed using a non-parametric
Mann–Whitney test. Data shown are mean 6 SEM, n¼ 3. Full uncut western blots are found in the Supplementary Material. LiCl ¼ lithium
chloride; OA ¼ okadaic acid; WT ¼wild type.
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Figure 5 BIN1 knockdown alters dendritic spine morphology. (A) Primary cortical neurons transduced with BIN1 shRNA (BIN1)
lentivirus or scrambled control shRNA (Scr) lentivirus at 5 DIV were transfected with a plasmid expressing eGFP and fixed at 23 DIV. Maximum
intensity projections were generated from Z-stacks acquired using I-SIM super-resolution imaging. Five to ten different neurons per condition
were analysed in each of three separate experiments, one dendrite from each cell was selected randomly for spine quantification and all branches
of that dendrite were analysed. Dendritic spines were classified as either filopodia, stubby, thin or mushroom spines (right). Bar charts show the
quantification of spine (B) length, (C) volume, (D) density, (E) head diameter, (F) neck diameter, (G) ratio of spine head to neck diameter and
percentage of (H) stubby, (I) thin, (J) mushroom spines and (K) filopodia. Data are mean 6 SEM and were analysed using a randomized block 2-
way ANOVA. n¼ 3. *P< 0.05 and **P< 0.01. eGFP ¼ enhanced green fluorescent protein.
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To directly ascertain the effects of BIN1 loss on tau lo-
calization, we knocked down BIN1 in rat primary neu-
rons and showed that this caused an accumulation of
phosphorylated tau at synapses. This finding is in
agreement with previous reports that over-expression of
BIN1 in mice expressing human tau leads to a reduced
number of somatodendritic tau inclusions (Sartori et al.,
2019). This is an important concept since alterations in
Figure 6 BIN1 knockdown reduces basal and stimulated tau release. (A) Cell lysates from 21 DIV primary cortical neurons
transduced with scrambled control shRNA (Scr) lentivirus or BIN1 shRNA (BIN1) lentivirus at 5 DIV were western blotted with antibodies
against BIN1 and total tau. (B) Quantification shows no effect of BIN1 knockdown on intracellular tau amount. Shapiro–Wilk normality test
demonstrated that the data were normally distributed, and so data were analysed using an unpaired T-test. (C) Tau content in conditioned media
from the same neurons was determined by ELISA. Extracellular tau amounts were quantified relative to intracellular tau from the same well, and
the data show reduced tau release upon BIN1 knockdown. Shapiro–Wilk normality test demonstrated that the data were normally distributed,
so data were analysed using an unpaired T-test. (D) Cells transduced as above were depolarized with 50 nM KCl (þ) for 30 min, and the lysates
were western blotted with antibodies against BIN1 and total tau. (E) KCl treatment had no effect on intracellular tau amounts. Shapiro–Wilk
normality test demonstrated that the data were normally distributed, so data were analysed using an unpaired T-test. (F) Tau in conditioned
media from KCl-stimulated cells was measured as described for basal conditions. Tau release from neurons in which BIN1 was knocked down
was reduced upon neuron depolarization with KCl. Shapiro–Wilk normality test demonstrated that the data were not normally distributed, so
data were analysed using a Mann–Whitney test. (G) Lactate dehydrogenase amounts were measured in medium from unstimulated () or KCl-
stimulated (þ) primary cortical neurons transduced with scrambled control shRNA (Scr) lentivirus or BIN1 shRNA (BIN1) lentivirus as above
and show no effect of treatment on cell viability. Shapiro–Wilk normality test demonstrated that the data were not normally distributed, so data
were analysed using a Kruskal–Wallis test with Dunn’s multiple comparison test. All graphs show mean 6 SEM, n¼ 7 (intracellular tau), n¼ 6
(tau release/intracellular tau and lactate dehydrogenase assay). *P< 0.05. Full uncut western blots are found in the Supplementary Material. ELISA
¼ enzyme-linked immunosorbent assay; KCl ¼ potassium chloride.
Tau-directed effects of BIN1 loss in Alzheimer’s disease BRAIN COMMUNICATIONS 2020: Page 13 of 16 | 13
D
ow
nloaded from
 https://academ
ic.oup.com
/braincom
m
s/article/2/1/fcaa011/5736128 by guest on 22 Septem
ber 2020
the trafficking and normal positioning of tau are consid-
ered to be early pathogenic changes in Alzheimer’s dis-
ease (Zempel and Mandelkow, 2014; Zempel and
Mandelkow, 2015; Guo et al., 2017). We also investi-
gated the effects of BIN1 knockdown on synapse struc-
ture and tau release, since in addition to promoting the
spread of tau pathology (Yamada, 2017), synapse func-
tion is important for the release of physiological forms of
tau and, therefore, the signalling functions of extracellular
tau (Gomez-Ramos et al., 2008). We show here that
BIN1 knockdown affects the morphology of dendritic
spines, a feature closely linked with synapse function
(Chidambaram et al., 2019). BIN1 knockdown caused an
increased abundance of spines with a larger head and
neck diameter and a higher ratio of mature mushroom
spines to immature filopodia. Although, in these experi-
ments, we transduced cells with BIN1 shRNA at DIV5, a
time at which neurons and synapses are still developing,
Sartori et al. (2019) have reported that BIN1 is not
expressed in vitro until DIV14. Therefore, the alterations
we observe in synapse morphology are not expected to
have occurred as a result of any developmental roles of
BIN1. In support of this, BIN1 over-expression in mice
results in the opposite changes to spines, leading to struc-
tural alterations in the hippocampus and memory deficits
(Daudin et al., 2018). Mushroom spines are considered
to be more stable and in general, as spine size increases
the number of AMPA receptors on the spine increases,
promoting synaptic strength (Hanley, 2008; Lee et al.,
2012; Woolfrey and Srivastava, 2016). This may appear
to be in contrast with our assertion that BIN1 knock-
down promotes synapse damage by directing phosphory-
lated tau into synapses. However, synapse enlargement is
reported to occur in the early stages of neurodegeneration
in Alzheimer’s disease (DeKosky and Scheff, 1990) as a
compensatory mechanism for the pre-synapse loss occur-
ring early in the disease process. A similar mechanism at
the post-synapse could explain the increased spine diam-
eter we report here. It is also possible that the effect of
altering BIN1 expression on dendritic spines is independ-
ent of its binding to tau. Schurmann et al. (2019) report
that BIN1 modulates vesicle trafficking from recycling
endosomes to the cell surface, thereby altering the surface
localization of AMPA receptors at the post-synapse.
Hence, alterations in vesicle trafficking may be another
mechanism by which BIN1 alters the structure of dendrit-
ic spines.
Finally, we demonstrate that reducing BIN1 expression
reduced tau secretion from neurons, both in basal condi-
tions and following neuronal depolarization. We previ-
ously showed that tau released from primary neurons is
largely intact, dephosphorylated (Pooler et al., 2012), and
others have shown that this form of extracellular tau has
important trans-cellular signalling functions (Gomez-
Ramos et al., 2008) distinguishing it from the aggregated,
cleaved and highly phosphorylated tau species implicated
in trans-synaptic tau spread/propagation (Wu et al.,
2016). Our results therefore suggest that BIN1 loss in
Alzheimer’s disease could reduce the availability of extra-
cellular tau, resulting in a loss of extracellular tau
function.
In conclusion, our data demonstrate that BIN1 binds in
a tau phosphorylation-dependent manner to P216 of tau.
We find that BIN1 is lost in Alzheimer’s disease cyto-
plasm and that this correlates with tau accumulation in
synapses and its loss from the cytoplasm. Modelling the
loss of BIN1 in Alzheimer’s disease in primary neurons
showed that when BIN1 is knocked down, phosphory-
lated tau accumulates at synapses. We also see that BIN1
loss causes alterations to synapse structure and disrupts
tau release. We hypothesize that disruptions to BIN1 pro-
teins in Alzheimer’s disease affect normal tau functions in
the extracellular space and promote phosphorylated tau-
mediated synaptotoxicity. These data provide a potential
mechanism by which polymorphisms near BIN1 may in-
crease Alzheimer’s disease risk.
Supplementary material
Supplementary material is available at Brain
Communications online.
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